BioSpace

Evommune inks molecular glue deal worth $1.1B biobucks to fill pipeline gap

Evommune is commiting $30 million upfront for Hinova Pharmaceuticals’ oral molecular glue degrader—a low-cost bet with a high probability of success, according to analysts, after clinical failures roiled the biotech’s internal pipeline earlier this year.

By BioSpace

1 min read
Evommune inks molecular glue deal worth $1.1B biobucks to fill pipeline gap
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights